| Filed On | Filing |
|---|---|
| 14 Oct 2022 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference of our report dated May 20, 2022, relating to the consolidated financial statements of Cend Therapeutics, Inc. appearing in Registration Statement No. 333-265638 on Form S-4, Amendment No. 1, ... |
| 04 Oct 2022 |
8-K/A: Other Events
On April 26, 2022, Caladrius Biosciences, Inc. (“Caladrius”), CS Cedar Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Caladrius (“Merger Sub”), and Cend Therapeutics, Inc. (“Cend” or the “Company”), a privately-h... |
| 11 Apr 2019 | 8-K/A: Regulation FD Disclosure |
| 14 Mar 2016 | 8-K/A: Costs Associated with Exit or Disposal Activities; Material Impairments |
| 30 Jun 2011 | 8-K/A: Changes in Registrant's Certifying Accountant |
| 14 Jun 2011 | 8-K/A: Regulation FD Disclosure |
| 06 Apr 2010 | 8-K/A: Changes in Registrant's Certifying Accountant |
| 05 Jan 2010 | 8-K/A: Financial Statements and Exhibits |
| 09 Sep 2009 | 8-K/A: Entry into a Material Definitive Agreement |
| 13 Feb 2003 | 8-K/A: Other Events |
| 08 Mar 1996 | 8-K/A: Financial Statements and Exhibits |
Loading...
